This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ProMIS Neurosciences Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

ProMIS Neurosciences's earnings have been declining at an average annual rate of -21.7%, while the Biotechs industry saw earnings growing at 32.1% annually. Revenues have been declining at an average rate of 8.3% per year.

Wichtige Informationen

-21.7%

Wachstumsrate der Gewinne

-4.0%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie51.1%
Wachstumsrate der Einnahmen-8.3%
Eigenkapitalrenditen/a
Netto-Margen/a
Letzte Ertragsaktualisierung31 Mar 2023

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

We're A Little Worried About ProMIS Neurosciences' (TSE:PMN) Cash Burn Rate

Oct 11
We're A Little Worried About ProMIS Neurosciences' (TSE:PMN) Cash Burn Rate

Despite Lacking Profits ProMIS Neurosciences (TSE:PMN) Seems To Be On Top Of Its Debt

Jun 23
Despite Lacking Profits ProMIS Neurosciences (TSE:PMN) Seems To Be On Top Of Its Debt

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

Mar 07
Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

Nov 19
Is ProMIS Neurosciences (TSE:PMN) A Risky Investment?

Aufschlüsselung der Einnahmen und Ausgaben

Wie ProMIS Neurosciences Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

TSX:PMN Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
31 Mar 230-2180
31 Dec 220-1880
30 Sep 220-1260
30 Jun 220-850
31 Mar 220-650
31 Dec 210-1040
30 Sep 210-820
30 Jun 210-810
31 Mar 210-920
31 Dec 200-420
30 Sep 200-520
30 Jun 200-520
31 Mar 200-520
31 Dec 190-620
30 Sep 190-720
30 Jun 190-820
31 Mar 190-820
31 Dec 180-720
30 Sep 180-620
30 Jun 180-520
31 Mar 180-520
31 Dec 170-520
30 Sep 170-520
30 Jun 170-420
31 Mar 170-310
31 Dec 160-310
30 Sep 160-210
30 Jun 160-210
31 Mar 160-210
31 Dec 150-210
30 Sep 150-110
30 Jun 150-210
31 Mar 150-210
31 Dec 140-210
30 Sep 140-310
30 Jun 140-210
31 Mar 140-210
31 Dec 130-21-1
30 Sep 130-21-1
30 Jun 130-210
31 Mar 130-210
31 Dec 120-212
30 Sep 120-312

Qualität der Erträge: PMN is currently unprofitable.

Wachsende Gewinnspanne: PMN is currently unprofitable.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: PMN is unprofitable, and losses have increased over the past 5 years at a rate of 21.7% per year.

Beschleunigtes Wachstum: Unable to compare PMN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Erträge im Vergleich zur Industrie: PMN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).


Eigenkapitalrendite

Hohe Eigenkapitalrendite: PMN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren